Table 3.
Prevalence of HPV types prevented by the Gardasil HPV vaccine and hypothetical vaccine protection against prevalent infectionsa
| American Indian | White | |||
|---|---|---|---|---|
| (n = 235) | (n = 246) | |||
| % | (95% CI) | % | (95% CI) | |
| Infected by HPV types prevented by Gardasil vaccine | ||||
| Type 6 | 1 | (0-3) | 1 | (0-2) |
| Type 11 | 1 | (1-3) | 0 | -- |
| Type 16 | 5 | (3-8) | 6 | (3-10) |
| Type 18 | 5 | (3-10) | 1 | (1-3) |
| Hypothetical protectiona by Gardasil against prevalent HPV infection | ||||
| Not applicable (no infection) | 58 | (51-65) | 77 | (71-82) |
| No protection | 32 | (26-38) | 15 | (11-21) |
| Partial protection | 5 | (3-8) | 2 | (1-4) |
| Full protection | 5 | (3-10) | 6 | (3-10) |
Prevalence estimates are standardized by age and lifetime number of sexual partners.
a Presumed protection against infection, assuming a counterfactual scenario in which each woman had been vaccinated before HPV exposure.